ImmunityBio/$IBRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
673
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$2.1B
-
-$0.42
-0.06
-
Price and volume
Market cap
$2.1B
Beta
-0.06
52-week high
$5.11
52-week low
$1.83
Average daily volume
9.5M
Financial strength
Current ratio
5.767
Quick ratio
5.103
Long term debt to equity
-162.649
Total debt to equity
-164.553
Interest coverage (TTM)
-2.12%
Profitability
EBITDA (TTM)
-244.947
Gross margin (TTM)
99.55%
Net profit margin (TTM)
-422.28%
Operating margin (TTM)
-315.84%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-36.89%
Return on equity (TTM)
55.02%
Valuation
Price to revenue (TTM)
22.387
Price to book
-4.06
Price to tangible book (TTM)
-3.95
Price to free cash flow (TTM)
-5.608
Free cash flow yield (TTM)
-17.83%
Free cash flow per share (TTM)
-0.385
Growth
Revenue change (TTM)
1,025.95%
Earnings per share change (TTM)
-52.80%
3-year revenue growth (CAGR)
429.21%
3-year earnings per share growth (CAGR)
-25.49%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Bulls say / Bears say
ANKTIVA commercial performance remains strong, with Q2 2025 net product revenue of $26.4 million (up 60% quarter-over-quarter) and year-to-date unit growth of 246% since J-code implementation (Business Wire)
ImmunityBio’s balance sheet strengthened with $153.7 million in cash and equivalents as of June 30, 2025, further supported by an $80 million equity financing in July 2025 (with up to $96 million available if warrants are exercised), backing the company’s operational runway and R&D investments (Business Wire, Business Wire)
FDA issued a Refusal to File letter on May 2, 2025 for Anktiva’s supplemental BLA in the papillary NMIBC indication, contradicting previous agency guidance and delaying potential label expansion (Investing.com, PharmExec)
High cash burn remains a concern, with pro forma cash of $136.4 million covering less than two quarters of the $85.9 million operating burn rate reported in Q1 2025, underlining the likelihood of further dilutive financings (Panabee)
Despite growing revenues, shares traded near a 52-week low of $1.83 on May 7, 2025, indicating limited investor confidence and continued valuation pressures (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Business Wire6 days ago
Biotech Breakouts: 3 Stocks With Massive Upside Potential
MarketBeat2 months ago
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.1B as of November 11, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of November 11, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.